Product Description
CSPC is developing tg-103, a subcutaneous agent for Type 2 Diabetes
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSPC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Obesity|Overweight|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SYSA1803-009 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2026-03-01 |
63% |
SYSA1803-010 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2026-03-01 |
63% |
SYSA1803-013 | P3 |
Not yet recruiting |
Overweight|Obesity |
2025-01-31 |
57% |
SYSA1803-017 | P2 |
Active, not recruiting |
Obesity|Overweight |
2024-12-31 |